[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"IWK Health Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":326},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,78,112,140,162,192,224,247,270,298],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100543543","phase-2-aprepitant-treatment-to-prevent-postoperative-nausea-and-vomiting-in-children-undergoing-scoliosis-surgery-100543543",false,"NCT06357234","Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery","A Randomized Controlled Trial Comparing Aprepitant to Standard of Care for Postoperative Nausea and Vomiting Prophylaxis in Children and Adolescents Undergoing Scoliosis Surgery: The APRE-PONV Trial","Inclusion Criteria:\n\n* Posterior Spinal Instrumentation and Fusion (PSIF) for idiopathic scoliosis\n* The fusion must include at least 6 vertebral levels.\n* Children greater than or equal to 8 years old, and less than 19 years old on the day of surgery\n* Weight \\> 40kg - for ease of pharmacy preparation (PONV dose 1mg per kg to max 40mg)\n\nExclusion Criteria:\n\n* Patient\u002F Parent refusal\n* Hypersensitivity to Aprepitant or any ingredient in the formulation or oral solution. (previous allergy or adverse reaction to Aprepitant)\n* Developmental delay as reported by parents\n* Pregnant - Pregnancy test done as standard of care pre-operative\n* Severe systemic disease ASA classification III or greater\n* Concurrent use of any medication with severe interaction with Aprepitant as outlined in product monograph.\n* Neuromuscular or congenital scoliosis\n* Inability to take PO medications","ALL","8 Years","19 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This research trial will measure how useful Aprepitant is in preventing nausea and vomiting in children having surgery to correct scoliosis (curvature of the spine).",[27,28,29],"Spinal Fusion","Nausea and Vomiting, Postoperative","Anesthesia",[31,32,33,34],"pediatric","anesthetic","scoliosis","Aprepitant","RECRUITING","2026-04-22",{"date":38,"type":39},"2026-04-27","ACTUAL",{"date":41,"type":39},"2025-03-17",{"date":43,"type":21},"2027-09",{"name":45,"class":46},"IWK Health Centre","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100455687","withholding-enteral-feeds-around-blood-transfusion-international-100455687","NCT05213806","WithHolding Enteral Feeds Around Blood Transfusion (International)","The WHEAT International Trial: WithHolding Enteral Feeds Around Red Cell Transfusion to Prevent Necrotizing Enterocolitis in Preterm Neonates: an International, Multi-centre, Randomized Controlled Trial","WHEAT","Inclusion Criteria:\n\n1\\. Preterm birth at \\\u003C30+0 gestational weeks + days\n\nExclusion Criteria:\n\n1. Parent(s) opt-out of trial participation.\n2. Packed red cell transfusion with concurrent enteral feeds prior to enrolment. (Infants who have received a packed red cell transfusion while nil-by-mouth are eligible; or minimal enteral nutrition (\\\u003C15 ml\u002Fkg\u002Fday feeds) at the time of transfusion; defined as before, during and for at least 4 hours after transfusion, are eligible.\n3. Infants who are not being fed at the time of randomization (\\\u003C15ml\u002Fkg) or where enteral feeding is contraindicated \\[e.g. Major congenital abnormality of the gastrointestinal tract (GIT)\\].\n4. Previous episode of NEC Bell stage 2 or higher or SIP prior to first study packed cell transfusion.","30 Weeks",{"count":58,"type":21},4333,[60],"NA","The WHEAT International trial is a comparative effectiveness trial exploring whether withholding enteral feeds around the time of blood transfusion in very premature infants (\\\u003C30 weeks) will reduce the occurrence of Necrotizing Enterocolitis (NEC). Currently both continued feeding and withholding feeding are approved care practices. The current study will randomize infants from Neonatal Intensive Care Units (NICUs) across Canada and the United Kingdom (UK) into one of the two care approaches (withholding or continued feeds) to determine if any significant outcomes are found.",[63],"Necrotizing Enterocolitis",[65,63,66,67,68],"Comparative Effectiveness Trial","Premature Infants","Blood Transfusion","Withholding enteral feeds","2026-04-21",{"date":71,"type":39},"2026-04-24",{"date":73,"type":39},"2022-01-28",{"date":75,"type":21},"2027-03-31",{"name":45,"class":46},40,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":47},"100592641","essential-coaching-postpartum-evaluating-a-parent-focused-postpartum-text-message-program-in-nova-scotia-100592641","NCT06996067","Essential Coaching Postpartum: Evaluating a Parent-focused Postpartum Text Message Program in Nova Scotia","INCLUSION CRITERIA:\n\nEligible birthing parents will\n\n* early postpartum (\\\u003C7 days) with their first child\n* understand English\n* have a cell phone with text and data\n* be 18 years of age or old\n* live in Nova Scotia.\n\nEligible non-birthing parents will:\n\n* be early postpartum (\\\u003C7 days) with their first child\n* understand English\n* have a cell phone with text and data\n* be 18 years of age or old\n* live in Nova Scotia.\n\nEXCLUSION CRITERIA:\n\nParticipants (both birthing and non-birthing parents) will be excluded if:\n\n* newborn die or are expected to die prior to leaving the hospital\n* they have no access to mobile phone, either personal or shared\n* unwilling to receive SMS messages\n* decline or withdraw to participate\n* participated in a previous iteration of this project (e.g., either the development or evaluation).",true,"18 Years",{"count":87,"type":21},332,[60],"The transition to parenthood is often an exciting yet hard period for parents. In the first year after a new baby, many parents feel less confident, have more anxiety and depression, and feel more isolated and alone. During this time, many parents use their phones and the Internet to seek out information and support. Thus, the investigators are exploring the opportunity of using mHealth, or mobile health, to provide information directly to parents after the birth of their first baby. The investigators have developed a program for both birthing and non-birthing parents called the Essential Coaching Postpartum program. This program provides 332 parents with text messages sent for 6 weeks after birth to share information on newborn care and parent outcomes. This will be tailored based on whether they are the birthing parent (Essential Coaching for Every Mother) or non-birthing parent (Essential Coaching for Every Partner). The investigators will evaluate this program by comparing a group of parents who receive the messages to a group of parents do not receive any text messages. To determine the success of the Essential Coaching Postpartum program, the investigators will compare parents' confidence, anxiety, depression, and co-parenting between the two groups after six-weeks and six-months. The investigators believe that parents who get the text messages will have higher confidence and co-parenting outcomes and lower anxiety and depression. The investigator's goal with the Essential Coaching Postpartum program is to help make the first few weeks after a new baby less stressful by providing information and support directly to parents that they know they can trust.",[91,92,93,94,95,96],"Parenting Self-efficacy","Postpartum Anxiety","Postpartum Depression (PPD)","Postpartum Stress","Mental Health","Co-parenting Practices",[98,99,100,101,102,103],"text messaging","non-birthing parent","birthing parents","mothers","fathers","digital health","2026-03-24",{"date":106,"type":39},"2026-03-27",{"date":108,"type":39},"2025-06-05",{"date":110,"type":21},"2027-06",{"name":45,"class":46},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100577344","app-based-migraine-treatment-the-health-ensuite-study-100577344","NCT06797076","App-Based Migraine Treatment: The Health enSuite Study","Evaluating an App-Based Treatment for Migraine: The Health enSuite Migraine Study","Inclusion Criteria (for study entry):\n\n* Fluent in English\n* Age 18 to 50 years\n* Regular access to an internet-connected device (e.g., smartphone, tablet, or computer)\n* Scores 2 or more on the ID Migraine Screener\n\nInclusion Criteria (for enrollment):\n\n* Completes at least 50% of the daily entries when asked to use the migraine headache tracker for a 28-day period\n* Experiences migraine headache on at least 4 days, but no more than 20 days, within the past month (based on diary data)\n\nExclusion Criteria:\n\n* Diagnosis of psychosis and\u002For schizophrenia\n* Physical or cognitive impairment that compromises ability to provide informed consent\n* Pregnancy, planning pregnancy during the study, or currently breastfeeding\n* Change in medications and\u002For dietary supplements (herbal supplements, minerals, vitamins) for migraine headache pain in the past month\n\nRationale for Eligibility Criteria:\n\nBehavioural and\u002For psychosocial treatment is not recommended for migraine headache related to conditions such as psychosis, and\u002For schizophrenia. While behavioral and psychosocial treatments may offer some benefits for individuals with migraine headache related to psychosis and schizophrenia, there are also potential risks to consider. For example, CBT may involve exploring painful feelings and experiences, which could be distressing for individuals with psychosis. This could potentially exacerbate psychotic symptoms or lead to emotional distress. Additionally, some individuals with schizophrenia may have difficulty engaging in CBT due to cognitive impairments, such as difficulty concentrating or remembering information, or paranoia. Therefore, potential participants who have any of these conditions will be excluded from the study.\n\nPregnancy and breastfeeding result in hormonal changes that can increase migraine headache symptoms. Thus, guidelines for headache trials highly suggest excluding participants who are planning to be pregnant, currently pregnant or are nursing their infants.\n\nThe initiation of other treatments for migraine headache at the same time as Health enSuite Migraine could jeopardize the interpretation of the trial results. They are permitted to continue using any pre-existing treatments (medications, dietary supplements, vitamins). If participants are taking any medications\u002F and or dietary supplements, they must have been taking them for at least one month to be eligible for enrollment in the trial. Participants are asked at the end of the trial if they have started any new medication while using Health enSuite Migraine; if the new medication taken is recognized to have impacted the results, the participant's data will be removed for data analysis.\n\nThe age range of 18-50 years was chosen to align with the typical demographic most affected by migraine headache and to ensure the app's design and content are appropriate for its intended users. Research indicates that migraine headaches are most prevalent in this age group, with peak incidence occurring during early adulthood and middle age. Additionally, individuals outside this range, such as adolescents or older adults, may have distinct physiological, psychological, and treatment needs that differ from those of the target demographic.\n\nFor example, older adults often experience migraine headache differently due to age-related comorbidities or medication interactions, which may require specialized interventions beyond the scope of this study or app. Similarly, the app's features and usability are tailored to adults with regular access to technology and familiarity with app-based interventions.\n\nThe Health enSuite Migraine program being tested in this trial requires the use of an internet-connected device. Health enSuite Migraine can be accessed through the web browser on an electronic device with an internet connection. People who do not have regular access to an internet-connected device are unlikely to benefit from Health enSuite Migraine, and therefore they will be excluded.\n\nParticipants must have experienced migraine headache pain at least four days out of each month. This criterion is intended to ensure that all participants will experience at least some migraine headache symptoms throughout the study. Chronic daily migraine headaches are especially difficult to treat through psychosocial intervention alone, therefore participants who report migraine headache on more than 20 days per month will be excluded. Apart from the above mentioned 8 criteria points, study eligibility will be evaluated based on one month of daily migraine headache tracking completed at baseline to ensure the participant experiences a migraine headache between 4 to 20 days within the past month","50 Years",{"count":121,"type":21},415,[60],"Health enSuite is a suite of applications designed by our research team at the Centre of Research in Family Health at IWK Health. These applications evaluate virtual solutions for clinical problems and assist family doctors with their adult patients.\n\nHealth enSuite will be utilized by Canadian family physicians targeting insomnia, anxiety, migraine headache, and caregiver distress.\n\nHealth enSuite Migraine has been designed to make cognitive and behavioral techniques for managing migraine headache readily available to primary care patients. The online program combines treatment elements that are effective in preventing and managing migraine headache pain, including trigger management, stress management, relaxation techniques, cognitive reappraisal, and psychoeducation.",[125,126,127],"Migraine","Migraine With Aura","Migraine Without Aura",[129,125,130],"Headache","Cognitive Behavioral Therapy","NOT_YET_RECRUITING","2026-01-26",{"date":134,"type":39},"2026-01-27",{"date":136,"type":21},"2026-02-15",{"date":138,"type":21},"2027-06-02",{"name":45,"class":46},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100434993","health-ensuite-caregivers-an-app-based-treatment-for-distressed-caregivers-of-persons-with-moderate-dementia-100434993","NCT04944420","Health enSuite Caregivers: an App-based Treatment for Distressed Caregivers of Persons With Moderate Dementia","Evaluating an App-based Treatment for Distressed Caregivers of Persons With Moderate Dementia: Health enSuite Caregivers Study","To be eligible for this trial, participants will have to satisfy the following criteria:\n\n1. The participant is 18 years or older.\n2. The participant has regular access to an internet connected device (e.g., smartphone, tablet, or computer).\n3. The participant is a caregiver of a person with moderate dementia.\n4. The participant provides a least one hour of care per week.\n5. The participant is experiencing distress associated with caregiving (score DQ5 \\>= 11).\n\nRational:\n\nHealth enSuite Caregivers program being tested in this trial requires the use of an internet connected device. Health enSuite Caregivers can be downloaded as a mobile application for use on a smartphone or tablet, or it can be accessed through the web browser on an electronic device with an internet connection. People who do not have regular access to an internet connected device are unlikely to benefit from Health enSuite Caregivers, and therefore they will be excluded.\n\nHealth enSuite Caregivers is designed to help primary caregivers of persons with moderate dementia. Therefore, the eligibility screening questionnaire includes items to assess dementia severity. To ensure that the participants has ongoing caregiving duties, they must self-report providing at least one hour of care per week. There is no clear consensus on the number of hours of care that all primary caregivers provide. Reports from the Canadian Institute for Health Informatics estimate that on average informal caregivers of persons with dementia provide 26 hours of care per week (3). One hour per week was selected as a minimum threshold to exclude people with very limited caregiving responsibilities.\n\nHealth enSuite Caregivers is intended to help caregivers who are experiencing some degree of distress. Participants must also score above the cut-off score (\\>=11) for distress on the DQ-5 (18), a population distress screening measure.",{"count":148,"type":21},400,[60],"Health enSuite Caregivers is an e-health program designed to meet some of the most common needs of caregivers of persons with dementia, including information about dementia and dementia care, caregivers' emotional health, formal or informal help received from others. It also recommends specific strategies to promote wellbeing and provides tools to help caregivers implement these strategies in their everyday lives. Health enSuite Caregivers is available online and as a smartphone app. Its development was informed by reviews of caregivers' needs and existing commercially available apps F. A systematic search of commercially available smartphone applications for caregivers found that many apps did not consider each caregiver's unique needs and were limited to psychoeducational content (no tools for self-management). Furthermore, most existing programs have not been rigorously tested or lack evidence to support their effectiveness.",[152],"Caregiver Burnout",[152,154,155,156],"Caregiver Stress","Caregivers","Dementia",{"date":134,"type":39},{"date":136,"type":21},{"date":160,"type":21},"2027-08",{"name":45,"class":46},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":56,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},"100614802","examining-the-efficacy-of-a-digital-media-intervention-to-increase-recruitment-rates-100614802","NCT07284329","Examining the Efficacy of a Digital Media Intervention to Increase Recruitment Rates","Examining the Efficacy of a Parent-targeted Co-designed Digital Media Intervention to Increase Recruitment Rates Across a Multi-site Randomized Clinical Trial in Canadian NICU's","WHEAT-Boost","Inclusion Criteria (applied to infants\u002Fparticipants in WHEAT Trial):\n\nInfant meets eligibility criteria for the WHEAT International Trial\n\nInfant is \\\u003C30 weeks gestational age at birth\n\nInfant is admitted to one of the participating Canadian NICU sites\n\nParent(s)\u002Fprimary caregiver(s) are approached for consent to participate in the WHEAT Trial during a time period when the SWAT is active at their site\n\nExclusion Criteria:\n\nInfant or family ineligible for participation in the WHEAT International Trial\n\nParent(s)\u002Fprimary caregiver(s) not approached for WHEAT Trial participation (e.g., missed recruitment window, language barriers not addressed by materials, medical instability of infant or family)",{"count":171,"type":21},787,[60],"WHEAT-Boost is a Study Within A Trial (SWAT) that aims to improve how families are recruited into neonatal research studies by testing a new way of sharing information. The study is embedded within the larger WHEAT International Trial, a randomized clinical trial being conducted in Neonatal Intensive Care Units (NICUs) across Canada. The WHEAT International Trial investigates the best way to manage feeding around the time of blood transfusions in very premature infants (born before 30 weeks of pregnancy).\n\nRecruiting families for research in the NICU is challenging. Parents are often stressed, overwhelmed, and unfamiliar with how clinical trials work, which can make it hard for them to process complex medical information and decide whether to take part. Traditional consent methods, such as paper forms, may not be enough to ensure families feel informed and comfortable with participation.\n\nTo address this, WHEAT-Boost will test whether adding a short, co-designed digital video helps improve recruitment rates. The video is 3.5 to 4 minutes long, available in English and French (with subtitles in other commonly spoken languages), and explains the importance of NICU research and details of the WHEAT International Trial in a simple and visual way. The video was co-developed with parents who have experience in the NICU to ensure the information is relevant and easy to understand.\n\nNICU sites participating in the WHEAT Trial will be randomly assigned, in a stepped-wedge design schedule, to either continue using their usual recruitment methods, or to add the digital video to their recruitment approach. Parents in both groups will be asked to complete a short, voluntary questionnaire about their experience with the consent process and their understanding of the trial.\n\nThe main goal of WHEAT-Boost is to see if the video increases the number of families who agree to take part in the WHEAT Trial (known as the \"opt-in rate\"). The study will also look at whether the video reduces the number of families who later withdraw from the trial, and whether it improves parents' understanding of the study and their satisfaction with how information was shared.\n\nIf successful, the video could be used in other NICUs or future studies to help make research more accessible and inclusive for families. This approach could lead to stronger participation in neonatal trials, better-informed decisions by parents, and faster progress in improving care for premature babies.",[175],"Consent Process",[177,178,179,180,181,182],"Consent","Neonatal research","Family questionnaires","Digital media","Co-design","Study video","2025-12-02",{"date":185,"type":39},"2025-12-16",{"date":187,"type":39},"2025-01-06",{"date":189,"type":21},"2026-04-30",{"name":45,"class":46},15,{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":209,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":221,"leadSponsor":223,"locationsCount":47},"100605689","brief-videos-delivered-by-text-messages-as-a-public-health-intervention-for-ptsd-in-youth-100605689","NCT07165782","Brief Videos Delivered by Text Messages as a Public Health Intervention for PTSD in Youth","Brief Videos Delivered by Text Messages as a Public Health Intervention for PTSD in Youth: A Feasibility and Acceptability Randomized Trial","Inclusion Criteria:\n\n* Likely diagnosis of PTSD as indicated by a minimum score of 31 on the Post Traumatic Stress Disorder Checklist\n* Direct exposure to actual or threatened death, serious injury, or sexual violence or through witnessing, learning it happened to a close relation as assessed by the Life Events Checklist\n* Between 15 and 25 years old at time of enrolment\n* Access to a mobile phone and a data plan that allows them to receive text messages and videos\n* Live in Canada\n\nExclusion Criteria:\n\n* Presence of active suicidality, determined by items from the Patient Safety Screener\n* Active symptoms of psychosis, indicated by a brief Psychosis Screener Questionnaire\n* An inability to read and\u002For understand English","15 Years","25 Years",{"count":202,"type":21},98,[60],"The goal of this clinical trial is to learn if informational videos (the intervention) sent by text messages can help young people (age 15 - 25) manage symptoms of post traumatic stress disorder (PTSD). This is a small-scale trial to evaluate whether the intervention has potential to be effective, whether it is feasible to carry out a bigger study, and whether youth find the intervention acceptable.The main questions it aims to answer are:\n\n1. Does the intervention help youth reduce their symptoms of PTSD, anxiety, and depression, improve how well they function day-to-day, and lead to post-traumatic growth.\n2. Will it be possible to conduct a larger study on the intervention (e.g., are we able to attract participants to take part in the study; do participants follow through with the intervention and the study) and is the intervention acceptable to youth (e.g., do they watch the videos, and rate the videos as useful, interesting, understandable, and relevant)?\n\nResearchers will compare those who receive the intervention right away to those who wait to receive the intervention to see if there are differences between groups.\n\nVideos will teach youth about PTSD and provide the opportunity to practice strategies that have been shown to help with reduce symptoms of PTSD, such as exposure, reducing avoidance, social support, and coping strategies (e.g., changing your thoughts, deep breathing, and muscle relaxation).\n\nThe study is fully online. Participants will be randomly placed in one of two groups:\n\n1. Intervention Group: Gets three PTSD-related text messages per week for 10 weeks. They will also be asked to rate each of the videos on how helpful you found them.\n2. Waitlist Group: Does not receive text messages until AFTER the final surveys for the study are completed (i.e., 5 months), then will receive the intervention.\n\nEveryone will be asked to complete online surveys about their mental health and functioning 3 times during the study:\n\n* Beginning of the study\n* 10 weeks into the study\n* 3 months after the videos end (end of study)",[206,207,208],"Post-Traumatic Stress Disorder in Adolescence","Post-Traumatic Stress Disorder, PTSD","Post-Traumatic Stress Disorder in Youth",[210,211,212,213,214,215,216],"posttraumatic stress disorder","post-traumatic stress disorder","trauma","public health","rct","text message","video intervention","2025-09-03",{"date":219,"type":39},"2025-09-10",{"date":219,"type":21},{"date":222,"type":21},"2026-12-30",{"name":45,"class":46},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":47},"100436349","health-ensuite-insomnia-an-app-based-treatment-for-adult-chronic-insomnia-100436349","NCT04962087","Health enSuite Insomnia: an App-based Treatment for Adult Chronic Insomnia","Randomized Controlled Trial to Evaluate Health enSuite Insomnia: an App-based Treatment for Adult Chronic Insomnia","To be eligible for this study, participants must meet all of the following criteria:\n\n* Age 18 years or older Rationale: The intervention is designed for adults. Sleep patterns, treatment needs, and legal capacity for consent differ in children and adolescents, so participants must be legal adults to provide informed consent and to ensure relevance of the treatment content.\n* Experience one or more insomnia symptoms (e.g., difficulty falling asleep, staying asleep, or waking too early) at least 3 times per week for at least 3 months Rationale: This criterion aligns with standard diagnostic criteria for chronic insomnia (e.g., DSM-5, ICSD-3 (9,10), ensuring that the intervention targets individuals with persistent and clinically meaningful symptoms.\n* Have access to an internet-connected device (e.g., smartphone, tablet, or computer) Rationale: The CBT-I program is delivered entirely online via a mobile app or web platform. Participants must have reliable access to an internet-enabled device to complete program content, questionnaires, and sleep diaries.\n* Not currently working regular overnight shifts (e.g., shifts starting between 10:00 PM and 12:00 AM and ending between 6:00 AM and 8:00 AM) Rationale: Night shift work disrupts circadian rhythms and sleep patterns in ways that are distinct from chronic insomnia. Individuals who work night shifts may not benefit from a standardized sleep schedule and could face difficulties adhering to the intervention.\n* Not currently a parent of an infant under 1 year of age Rationale: Caring for an infant often involves frequent nighttime awakenings and irregular sleep patterns that are not necessarily reflective of insomnia. These participants may be unable to maintain a consistent sleep schedule as required by the intervention.\n* Not currently pregnant or trying to become pregnant. Rationale: Sleep disturbances during pregnancy often result from physiological and hormonal changes, which differ from behavioral insomnia. The program has not been designed or tested for use during pregnancy, and eligibility will change if pregnancy occurs during the study.\n* Have a total score greater than 7 on the Insomnia Severity Index (ISI) (11), indicating at least mild insomnia symptoms.\n\nRationale: The ISI is a validated tool used to assess the severity of insomnia symptoms. A score of 8 or more indicates at least mild insomnia, which supports the need for intervention. Excluding participants with minimal or no symptoms ensures that the program is delivered to those who stand to benefit and that changes in symptoms are measurable.",{"count":121,"type":21},[60],"This project consists of a randomized controlled trial. The objective of this trial is to test the effectiveness of an app-based cognitive behavioral program for insomnia (Health enSuite: Insomnia) in reducing insomnia symptoms.",[235],"Insomnia",[235,237,238],"Deprescribing","Cognitive Behavioural Therapy","2025-08-22",{"date":241,"type":39},"2025-08-29",{"date":243,"type":39},"2024-08-29",{"date":245,"type":21},"2026-07-01",{"name":45,"class":46},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":84,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":47},"100590512","the-covid-dome-trial-100590512","NCT06968377","The COVID Dome Trial","Preliminary Clinical Evaluation of a Novel Airborne Pathogen Containment Device Design: Randomized Open-label Equivalence Trial of Patient Safety and Acceptability During Endotracheal Intubation.","Inclusion Criteria:\n\n* ASA class 1 and 2\n* Elective surgery\n* Adults \\>18 years of age\n* Ability to give informed consent\n* Surgery in supine or lithotomy position\n* Surgical site: abdominal, pelvic, lower limb or distal upper limb\n* Endotracheal intubation is indicated as per attending anesthesiologist\n\nExclusion Criteria:\n\n* BMI \\>40\n* pregnancy\n* \"full stomach\" or increased intraabdominal pressure (as per attending anesthesiologist)\n* predictors of difficult airway management as per attending anesthesiologist\n* airway management plan (as per attending anesthesiologist) that is incompatible with study protocol\n* initial ventilatory settings that are incompatible with planned care as per study protocol\n* anxiety disorder (including claustrophobia)\n* significant cardiovascular or respiratory disease (including pleural effusion, pulmonary edema, etc.)\n* anticipated significant level of post-operative sedation preventing survey participation",{"count":255,"type":21},80,[60],"The aim of this study is to test a bubble-like dome (made of clear plastic) being placed over patients' heads during surgery as a tool to prevent the spread of germs through the air in hospitals.\n\nThe researchers are interested in the following outcomes:\n\n* How the device affects the patients' experience of surgery.\n* The impact of the device on how long it takes to place a breathing tube, blood pressure, heart rate and oxygen levels of the patient.\n\nResearchers will compare the outcomes across patients using the device and patients not using the device. This will be done by randomly (by chance) assigning participants undergoing surgery to group 1 (using the bubble-like dome device) or group 2 (not using the device).\n\nParticipants will:\n\n* Tell the researchers or your anesthesia doctor about any problems that you experience that you think might be related to participating in the study.\n* Fill out a 10-minute survey regarding your experience with the dome after surgery.\n* If you did not try the dome before going to sleep, you will be able to watch a video of the dome in use and answer questions based on the video\n* Be video recorded with your time with the dome.",[259,260,261],"Medical Device","Medical Device Performance","Aerosol Generating Procedure","2025-05-06",{"date":264,"type":39},"2025-05-13",{"date":266,"type":21},"2025-05-15",{"date":268,"type":21},"2026-05-15",{"name":45,"class":46},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":277,"minAge":85,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":282,"conditions":283,"keywords":286,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":47},"100495497","phase-4-evaluating-the-effect-of-intravenous-dexamethasone-on-the-duration-of-spinal-anesthesia-after-cesarean-delivery-100495497","NCT05731960","Evaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia After Cesarean Delivery","A Randomized Controlled Trial Evaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia as Part of a Multimodal Antiemetic Strategy for Enhanced Recovery After Cesarean Delivery","Inclusion Criteria:\n\n* Non-emergent Caesarean Delivery with planned spinal anesthesia\n* American Society of Anesthesia physical status class \\\u003C III\n* Age ≥18 years\n* Term gestational age (≥37weeks)\n* Singleton pregnancy\n* Moderate English language fluency\n\nExclusion Criteria:\n\n* Obesity (BMI ≥ 45kg\u002Fm2)\n* Height \\\u003C 5'0\"\n* Patients with significant obstetric or neonatal co-morbidities (i.e., severe maternal cardiac disease, preeclampsia, fetal anomalies)\n* Opioid tolerance or sensitivity\n* Intolerance to non-steroidal anti-inflammatory drugs (NSAIDs)\n* Contraindication to neuraxial analgesia (i.e., coagulopathy, infection, neuropathy)\n* Abnormal spinal anatomy (i.e., severe scoliosis, spina bifida, spinal instrumentation)\n* Use of chronic steroids\n* A physical or psychiatric condition which impairs cooperation","FEMALE",{"count":279,"type":21},192,[281],"PHASE4","The goal of this clinical trial is to determine the effects of intravenous (IV) dexamethasone on spinal anesthesia in healthy women having an elective Cesarean delivery (CD) at the IWK Health Centre. The main questions it aims to answer are:\n\n1. What effect does IV dexamethasone have on the resolution of motor blockade in patients having spinal anesthesia for elective CDs?\n2. What effect does IV dexamethasone have on the sensory recovery of spinal blockade, the total hydromorphone requirement in the first 24 h postoperatively, the incidence of pruritis perioperatively, and the incidence of nausea and vomiting?\n\nThe spinal anesthesia technique will be standardized and will be administered as per routine care at IWK Health. Computer generation will randomize patients to either Group SD, who will receive IV dexamethasone, or group SM who will receive IV metoclopramide, an alternative anti-emetic, immediately after spinal anesthesia by the attending anesthesia provider. Each patient will receive ondansetron, a second anti- emetic as recommended for Enhanced Recovery After Surgery (ERAS) protocol. Participant sensation, pain, nausea, pruritus, and motor blockade will be assessed in recovery. The patient's sensation and Bromage score will be assessed every 15 minutes until sensation is reached at L3 and a Bromage score of 4 is achieved.\n\nThe investigators will determine if there is a difference between groups regarding motor blockade, the length of time of spinal anesthesia, and side effects after CD.",[284,285],"Spinal Anesthesia","Dexamethasone",[287,288,289],"spinal anesthesia","dexamethasone","motor block","2024-07-05",{"date":292,"type":39},"2024-07-08",{"date":294,"type":39},"2023-03-06",{"date":296,"type":21},"2025-12",{"name":45,"class":46},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":325},"100440119","phase-3-selective-early-medical-treatment-of-patent-ductus-arteriosus-in-extremely-low-gestational-age-infants-a-pilot-rct-100440119","NCT05011149","Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT","Selective Early Medical Treatment of the Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot Randomized Controlled Trial","SMART-PDA","Inclusion Criteria:\n\n* Preterm infants less than 26 completed weeks (i.e., up to and including 25 weeks and 6 days) of gestation\n\nExclusion Criteria:\n\n* no PDA on initial screening echocardiography\n* congenital heart disease (excluding patent foramen ovale, atrial septal defect or ventricular septal defect with a defect size less than 2mm)\n* other major congenital anomaly\n* decision to withhold\u002Fwithdraw care","72 Hours",{"count":20,"type":21},[309],"PHASE3","Background: Among preterm infants, those born at a gestational age less than 26 weeks are considered the most vulnerable with a high risk of short- and long-term health problems that include chronic lung disease, brain bleeds, gut injury, kidney failure and death. Patent ductus arteriosus (PDA) is the most common heart condition with almost 70% preterm infants in this gestational age group being diagnosed with a PDA. Though many PDAs spontaneously resolve on their own, research suggests that if the PDA persists, it may contribute to a number of these short- and long-term health problems. Non-steroidal anti-inflammatory medications such as ibuprofen are commonly used to treat a PDA. Such drugs can also have harmful effects on the gut and kidneys of extremely preterm infants. Therefore, we are unsure if early treatment of a symptomatic PDA in this age group is at all beneficial. Given the wide variation in PDA treatment approaches in this age group, a randomized trial design, where extremely preterm infants with a symptomatic PDA are randomly assigned to early treatment or no early treatment, is essential to address this question.\n\nPurpose of the study: The overall purpose of this pilot study is to assess the feasibility of conducting a large study to explore the following research question: In preterm infants born \\\u003C26 weeks' gestation, is a strategy of selective early medical treatment of a symptomatic PDA better than no treatment at all in the first week of life?\n\nThe main feasibility objectives of this study are:\n\n1. To assess how many eligible infants can be enrolled in the study\n2. To assess how many enrolled infants properly complete the study protocol\n\nImportance: To our knowledge this will be the first study on PDA management in preterm infants that specifically aims to enroll preterm infants born at \\\u003C26 weeks of gestational age who are at the highest risk for PDA-related problems but have been mostly under-represented in previous PDA studies.",[312],"Patent Ductus Arteriosus After Premature Birth",[314,315,316],"extremely preterm infant","early medical treatment","randomized controlled trial","2024-06-18",{"date":319,"type":39},"2024-06-21",{"date":321,"type":39},"2022-01-10",{"date":323,"type":21},"2024-09-30",{"name":45,"class":46},9,""]